Hypercalcemia n = 24 | Normocalcemia n = 18 | P value | |
---|---|---|---|
Gender, male, n (%) | 13 (59%) | 9 (41%) | 1 |
Height, cm, mean ± SD | 164.19 ± 12.02 | 165.35 ± 8.66 | 0.738 |
Weight, kg, mean ± SD | 66.38 ± 12.76 | 70.81 ± 14.1 | 0.265 |
BMI, kg/m2, median (IQR) | 22.45 (20.49–26.88) | 26.33 (23.67–28.6) | 0.057 |
Ca, mmol/L, mean ± SD | 2.75 ± 0.2 | 2.43 ± 0.13 | < 0.001** |
iCa, mmol/L, median (IQR) | 1.35 (1.32–1.45) | 1.21 (1.19–1.22) | 0.002** |
Albumin, g/L, mean ± SD | 41.43 ± 4.93 | 43.94 ± 3.78 | 0.082 |
PTH, pg/mL, median (IQR) | 147.35 (75.55–270) | 48.3 (33.35–75.3) | 0.001** |
P, mmol/L, median (IQR) | 0.94 (0.8–1.22) | 1.04 (0.98–1.36) | 0.044* |
Age, years , mean ± SD at | |||
Initial symptoms | 31.88 ± 16.36 | 28.17 ± 11.53 | 0.417 |
Insulinoma diagnosis | 36.63 ± 17.06 | 31.67 ± 12.47 | 0.304 |
MEN1 diagnosis | 38.50 ± 15.41 | 31.67 ± 12.47 | 0.131 |
Delay of diagnosis of, median (IQR), years | |||
Insulinoma | 2 (1–6) | 2.5 (1–3.25) | 0.777 |
MEN1 | 6 (2.25–11) | 2.5 (1–4.75) | 0.045* |
Hypoglycemia related indexes, mean ± SD | |||
Glucose, mmol/L | 2.35 ± 0.59 | 2.18 ± 0.47 | 0.329 |
Insulin, μIU/mL | 14.49 (6.83–23.15) | 51.14 (33.65–71.54) | < 0.001** |
C-peptide, ng/mL | 3.09 ± 1.7 | 4.11 ± 1.78 | 0.085 |
INS/GLU | 5.77 (2.71–13.1) | 22.58 (13.68–29.98) | < 0.001** |
C-P/GLU | 1.38 ± 0.91 | 1.95 ± 1.04 | 0.081 |
Matsuda-ISI, mean ± SD | 73.72 ± 42.35 | 59.68 ± 43.7 | 0.414 |
Number of pNETs, n (%) | |||
Multiple | 20 (83.3%) | 10 (55.6%) | 0.104 |
Single | 4 (16.7%) | 8 (44.4%) | |
Maximum diameter of pNETs, cm, mean ± SD | 2.31 ± 1.17 | 1.92 ± 0.58 | 0.112 |
Tumor grade, n (%) | |||
Grade 1 | 8 (61.5%) | 11(68.8%) | 0.714 |
Grade 2 | 5 (38.5%) | 5(31.2%) | |
Histopathological Ki67% of surgery samples biopsy,%, mean ± SD | 2.82 ± 1.83 | 2.22 ± 1.3 | 0.894 |
Mitotic figures,%, median (IQR) | 1 (1–4) | 2 (1–3) | 0.776 |